Investigation of the Antibacterial Activity and Efflux Pump Inhibitory Effect of R.Br. Extract Against Clinical Isolates
Overview
Affiliations
The vast spread of multidrug-resistant bacteria has encouraged researchers to explore new antimicrobial compounds. This study aimed to investigate the phytochemistry and antibacterial activity of R.Br. leaves extract against clinical isolates. The minimum inhibitory concentration (MIC) values of extract ranged from 4 to 32 µg/mL. The impact of the treatment of the isolates with sub-inhibitory concentrations of extract was investigated on the bacterial growth, membrane integrity, inner and outer membrane permeability, membrane depolarization, and bacterial morphology using a scanning electron microscope (SEM) and on the efflux activity using qRT-PCR. Interestingly, most isolates treated with extract showed growth inhibition-a decrease in membrane integrity. In addition, we observed various morphological changes, a significant increase in inner and outer membrane permeability, a non-significant change in membrane depolarization, and a decrease in efflux activity after treatment. The phytochemical investigation of extract revealed the isolation of one new biflavonoid, 5,7,7″,4‴-tetra--methyl-hinokiflavone (), and five known compounds, stigmasterol (), naringenin (), 2,3-dihydrobilobetin (), 4',4‴-dimethyl amentoflavone (), and hinokiflavone (), for the first time. Moreover, the pure compounds' MICs' ranged from 0.25 to 2 µg/mL. Thus, could be a potential source for new antimicrobials.
Norouzalinia F, Asadpour L, Mokhtary M Int Microbiol. 2024; 28(3):563-573.
PMID: 39105888 DOI: 10.1007/s10123-024-00560-4.
Next-generation probiotics: the upcoming biotherapeutics.
Al-Fakhrany O, Elekhnawy E Mol Biol Rep. 2024; 51(1):505.
PMID: 38619680 PMC: 11018693. DOI: 10.1007/s11033-024-09398-5.
Alqahtani J, Negm W, Elekhnawy E, Alqahtani M, Moglad E, Ibrahim S Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399474 PMC: 10892485. DOI: 10.3390/ph17020259.
Role of fenofibrate in multiple sclerosis.
Abulaban A, Al-Kuraishy H, Al-Gareeb A, Elekhnawy E, Alanazi A, Alexiou A Eur J Med Res. 2024; 29(1):113.
PMID: 38336772 PMC: 10854163. DOI: 10.1186/s40001-024-01700-2.
Irisin/PGC-1α/FNDC5 pathway in Parkinson's disease: truth under the throes.
Ali N, Alhamdan N, Al-Kuraishy H, Al-Gareeb A, Elekhnawy E, El-Saber Batiha G Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):1985-1995.
PMID: 37819389 DOI: 10.1007/s00210-023-02726-9.